A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.
The long-term control of brain metastases becomes a clinical challenge. Whole brain
radiotherapy, the standard treatment for patients with multiple brain metastases, can only
bring a modest survival improvement around 3-6 months. EGFR-TKIs like icotinib with its
proven activity in non-small cell lung cancer may provide clinical benefits in such
patients.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and tolerability
All cause adverse events (AEs) and serious adverse events (SAEs)
6-12 months
Yes
You Lu
Principal Investigator
West China Hospital
China: Food and Drug Administration
BD-IC-IV04
NCT01516983
December 2011
September 2013
Name | Location |
---|